Featured Paper of the Month – December 2025
Published in Translational Psychiatry by Omar Soler-Cedeño and Zheng-Xiong Xi, M.D., Ph.D. of the NIDA IRP Addiction Biology Unit.
Summary
Cocaine addiction remains a major health challenge with no FDA-approved medications. This study evaluated two new compounds in animal models: RDS-04-010, an atypical dopamine transporter (DAT) inhibitor that binds to an inward-facing conformation of DAT, and RDS-03-094, a more typical DAT inhibitor that binds to an outward-facing conformation. Notably, RDS-04-010 reduced cocaine use, lowered motivation to seek cocaine, and prevented relapse-like behavior, while showing no rewarding or addictive effects on its own. In contrast, RDS-03-094 behaved more like cocaine and displayed addictive potential. These findings highlight RDS-04-010 as a promising treatment candidate and show how subtle differences in DAT binding can differentially influence cocaine-related behaviors.
Publication Information
RDS-04-010: a novel atypical DAT inhibitor that inhibits cocaine taking and seeking and itself has low abuse potential in experimental animals Journal Article
In: Transl Psychiatry, vol. 15, no. 1, pp. 182, 2025, ISSN: 2158-3188.

